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Abstract
Remote ischaemic conditioning (RIC) is a promising method of cardioprotection, with numerous clinical studies having 
demonstrated its ability to reduce myocardial infarct size and improve prognosis. On the other hand, there are several clini-
cal trials, in particular those conducted in the setting of elective cardiac surgery, that have failed to show any benefit of RIC. 
These contradictory data indicate that there is insufficient understanding of the mechanisms underlying RIC. RIC is now 
known to signal indiscriminately, protecting not only the heart, but also other organs. In particular, experimental studies have 
demonstrated that it is able to reduce infarct size in an acute ischaemic stroke model. However, the mechanisms underlying 
RIC-induced neuroprotection are even less well understood than for cardioprotection. The existence of bidirectional feedback 
interactions between the heart and the brain suggests that the mechanisms of RIC-induced neuroprotection and cardioprotec-
tion should be studied as a whole. This review, therefore, addresses the topic of the neural component of the RIC mechanism.
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Introduction
It is almost 25 years since the phenomenon of remote ischae-
mic preconditioning (RIPre) was discovered by Przyklenk 
et al. [106]. They demonstrated in a canine model that a 
series of brief, alternating episodes of ischaemia and reper-
fusion, applied to one area of the left ventricle (LV) myocar-
dium, protected a remote myocardial territory of the same 
heart from a subsequent prolonged ischaemic insult followed 
by reperfusion, limiting infarct size by almost 70%. In the 
same year, McClanahan et al. [94] achieved a similar infarct-
limiting effect in rabbits by applying a single 10-min episode 
of ischaemia to a kidney prior to 30-min occlusion of the 
left anterior-descending coronary artery. However, since the 
RIPre stimulus must, by definition, be applied before the 
onset of ischaemia, it is clear that the only possible clinical 
niche for the RIPre phenomenon in cardioprotection could 
be in the setting of either elective cardiac surgery or elective 
percutaneous coronary intervention (PCI)—scenarios when 
the onset and the duration of ischaemia are carefully con-
trolled (Fig. 1).
Twelve years after the discovery of RIPre, it was shown 
in a rat model that remote ischaemic conditioning (RIC) 
could be applied to a limb during myocardial ischaemia, and 
reduce infarct size by 50% [77]. This phenomenon became 
known as remote ischaemic preconditioning (RIPer). The 
next step in the study of RIC came with the demonstration by 
Andreka et al., that RIC could be successfully administered 
simultaneously with the onset of myocardial reperfusion—
a phenomenon named as remote ischaemic postcondition-
ing (RIPost) [1]. Taking this one step further, Basalay et al. 
demonstrated in a rat model of acute myocardial infarction 
that RIPost applied after a 10-min delay following the onset 
of reperfusion was still able to reduce infarct size similarly 
to RIPre [5]. Notably, the results included in this study were 
obtained in three research centres, using identical protocols 
[5]. The success of this procedure, termed ‘delayed RIPost’, 
was unexpected, in view of the prevailing hypothesis that 
the majority of myocardial reperfusion cell death is due to 
the opening of mitochondrial permeability transition pores 
(mPTP), thought to occur during the first few minutes of 
reperfusion [29, 46]. However, a series of studies demon-
strated implication of non-mPTP/necrosis mechanisms in 
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myocardial death [59] including pyroptosis [147], necrop-
tosis [12, 127], and, more controversially, apoptosis [67]. 
We appreciate that the Basalay study is the only one to-date 
reporting the benefit of delayed RIPost [5], and is, there-
fore, still awaiting independent confirmation. Nonetheless, 
the clinical potential of this cardioprotective phenomenon 
can be significant, as it potentially broadens the time frame 
during which myocardial injury can be prevented. Moreover, 
the possibility to protect myocardium beyond the first few 
minutes of reperfusion has also been supported by studies 
from the groups of Ovize, Marbán and others [4, 27, 38, 71, 
116], which have demonstrated cardioprotection with inter-
ventions applied up to the 20th min (rats, isolated rat hearts) 
[27, 38], 30th min (minipigs, mice) [71, 116] or 45th min 
(rats) [4] of myocardial reperfusion.
Though RIPre first emerged as a laboratory phenomenon, 
the cardioprotective potential of RIC strategies has subse-
quently drawn the attention of numerous clinical research 
groups [15, 28, 31, 36, 40, 82, 96, 105, 133, 135, 141]. In 
contrast to the repeated failures to translate cardioprotection 
from animal studies to clinical practice [42, 51, 59], RIC still 
appears to be a promising candidate for clinical use based 
both on the large number of successful experimental studies 
[17] and the fact that it satisfied all the recommendations for 
preclinical trials on cardioprotection [53, 56, 59, 86, 87].
The majority of clinical studies to date have demonstrated 
the infarct-limiting effect of RIC [15, 21, 28, 36, 105, 141] 
and improved outcome [40, 125] as a result of this procedure 
in patients with STEMI. The one exception is a recent study 
with neutral results, however, no long-term outcome data 
are currently available from this study [135]. In the setting 
of elective cardiac surgery, a single-centre trial involving 
329 patients with isoflurane, used for the maintenance of 
anesthesia, suggested that RIPre provided perioperative 
myocardial protection [133] and improved the prognosis 
over 1.54 years [133] and 5 years, respectively [81]. Another 
small-scale clinical study on patients undergoing elective 
aortic valve replacement, demonstrated that RIPre reduced 
myocardial injury if applied on a background of sevoflurane, 
but not propofol anesthesia [9, 10]. Two, large, multicentre 
clinical trials on cardiac surgery patients using propofol for 
anesthesia [31, 96], and one small clinical study with periop-
erative anesthesia restricted to sevoflurane and fentanyl [99] 
failed to show any benefits of using RIPre. Bearing in mind 
Fig. 1  Schematic time lines 
representing the concepts of 
remote ischaemic pre-, per-, 
post- and delayed postcondition-
ing, and the clinical scenarios 
in which they may be relevant. 
STEMI ST-elevated myocar-
dial infarction. Asterisk—the 
evidence for the existence of 
the delayed remote ischaemic 
postconditioning phenomenon 
is currently limited having 
only been demonstrated in one 
experimental study
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the success of the previous (proof of concept) clinical trials 
both in STEMI patients and in patients undergoing cardiac 
surgery, these neutral results indicate the gaps in the knowl-
edge of the mechanisms underlying the RIC phenomena, as 
well as lack of the differences between the mechanisms of 
myocardial ischaemia/reperfusion injury in these two clini-
cal settings. It is, therefore, imperative to investigate the 
mechanism of RIC to facilitate the translation of this simple, 
non-invasive, low-cost intervention into patient benefit. Two 
large-scale multicentre clinical trials on STEMI patients are 
ongoing (NCT02342522; NCT01857414). Their results, due 
in 2019, will shed more light on the effects and possible 
confounding factors of cardioprotection by RIC.
The mechanisms of cardioprotection 
by remote ischaemic conditioning 
with regard to translational aspects
After the discovery of RIPre, two main competing hypoth-
eses evolved regarding the mechanism of signal transduction 
from the preconditioned limb to the protected heart, one 
called the ‘humoral hypothesis’ and the other—the ‘neural 
hypothesis’. The humoral hypothesis is based on the fact that 
RIC-induced cardioprotection can be transferred to a naïve 
animal via whole blood transfusion [32]. Conversely, Gho 
et al. demonstrated that the neural blocker, hexamethonium, 
abolished cardioprotection by brief mesenteric artery occlu-
sion [43], suggesting the important role for the autonomic 
ganglia in RIPre. However, in a later study by Weinbren-
ner et al., hexamethonium failed to inhibit the protection 
afforded by RIPre, performed as infrarenal occlusion of the 
aorta [140]. This result, as well as the necessity for a reper-
fusion period interspaced between the RIPre and myocardial 
ischaemia, during which time the humoral factor could travel 
to the heart, were viewed as reasons to exclude the hypoth-
esis of a neuronal signal transmission from the remote area 
to the heart [140].
In 2010, Gourine et  al. proposed the existence of a 
‘remote preconditioning reflex’—a neural pathway of car-
dioprotection which is recruited by RIPre and protects the 
heart against ischaemia and reperfusion injury [44] (Fig. 2). 
This idea was supported by the data indicating the pres-
ence of all the components necessary for the realization of 
a classical reflex in the pathway mediating cardioprotection 
by RIPer: sensory (afferent) C-fiber neurons, an integration 
centre in the central nervous system, and motor (efferent) 
vagal neurons. In this regard, it has been demonstrated in 
a rat model of myocardial ischaemia/reperfusion injury, 
that cardioprotection by RIPre is completely abolished by 
denervation of the limbs performed as either mechanical 
transection of nerves [5, 130] or blocking afferent C-fibers 
by neonatal capsaicin treatment [5]. Similarly, stimulation of 
C-fiber afferents by topical capsaicin application limits myo-
cardial injury, mimicking the effect of RIPre [5, 112]. It has 
been shown that calcitonin gene-related peptide (CGRP)—
an important mediator of sensory neurons—mediates cardio-
protection by RIPre [142]. Abrogation of protection by RIC 
with spinal cord transection at T7–T10 level [34], or with 
intrathecal spinal opioid receptor blockade [143], confirmed 
the involvement of the neural afferent pathway. The effec-
tor arm of the RIPer reflex appears to involve parasympa-
thetic innervation. In the studies by Basalay et al., bilateral 
vagotomy in a rat model abolished cardioprotection induced 
by either RIPre [5, 6] or RIPer [6]. Mastitskaya et al. went 
further and directly inhibited parasympathetic motor neu-
rons which are known to be located in two distinct brain-
stem sites [93]. This resulted in complete abolishment of 
the infarct-limiting effect of RIPre [93]. Notably, this study 
was the first to provide direct evidence for the involvement 
of vagal efferents in RIPre-mediated cardioprotection. It 
is noteworthy that bilateral vagotomy in the Basalay et al. 
study did not attenuate the infarct-limiting effect of delayed 
RIPost [5], which suggested that the mechanisms underly-
ing these two phenomena may be distinct. Surprisingly, in 
a recent study by Buchholz et al., vagal stimulation in mice 
reduced myocardial infarct size when applied either before 
ischaemia or at the onset of reperfusion [18]. However, this 
study also revealed the difference in cardioprotective mecha-
nisms of these two time-periods of vagal stimulation: the 
first activated the Akt/GSK-3β muscarinic pathway, while 
the second activated α7nAChR and JAK-2, independently of 
the cholinergic anti-inflammatory pathway [18]. The results 
of these studies [5, 18] raise the possibility that additive 
benefit could be achieved by combining different types of 
RIC. A recent study by Kleinbongard et al. confirms the 
neuronal transfer of the protective signal during RIC [78]. 
In this study, RIC was demonstrated to attenuate ischaemia-
induced ST-segment elevation on the ECG during ongoing 
coronary artery occlusion [78].
Yellon’s group were the first to demonstrate the involve-
ment of both neural and humoral pathways in RIPre [89]. 
They found that in an RIPre model of femoral artery occlu-
sion in mice, the absence of venous blood return from the 
preconditioned limb, or combined femoral and sciatic nerve 
resection, completely abolished the infarct-limiting effect. 
Moreover, resection of only one nerve—either femoral 
or sciatic—only partially abolished this effect [89]. In an 
elegant study, Jensen et al. confirmed the requirement for 
both the neural and humoral pathways in RIPre-mediated 
cardioprotection by testing whether human plasma dialysate 
obtained after RIC could reduce infarct size and improve 
hemodynamic recovery in isolated rabbit hearts [64]. They 
showed that the plasma dialysate was protective if obtained 
from healthy subjects or diabetic subjects without peripheral 
neuropathy, but when obtained from diabetic patients with 
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neuropathy it was not protective. These findings further indi-
cate that the mechanism of a humoral factor release involves 
neural pathways [64].
Because the initial studies investigating the role of the 
autonomic ganglia in RIPre-mediated cardioprotection had 
been controversial [43, 140], this question was re-visited by 
Yellon’s group in 2016 [102, 103]. They demonstrated that 
plasma dialysate obtained from RIPre-treated rats reduced 
infarct size in naïve isolated hearts subjected to ischaemia 
and reperfusion. However, the plasma was no longer cardio-
protective if collected from vagotomised animals, or if the 
ganglionic blocker hexamethonium or muscarinic antagonist 
atropine were applied to isolated hearts [103]. This led to 
the conclusion that release of a protective factor following 
RIC is dependent on prior activation of the vagus nerve. In 
addition, the factor appears to induce cardioprotection via 
Fig. 2  Neural mechanisms of remote ischaemic preconditioning. 
A diagram of connections (both known and controversial) between 
the neural and humoral mechanisms of remote ischaemic precondi-
tioning of the heart and the brain. The core of this mechanism is the 
‘remote preconditioning reflex’ comprising afferent somatic nerves, 
integration centre/centres in the central neural system, and efferent 
vagal nerves, innervating the heart and other organs, specifically, the 
intestine. However, it is not certain whether the increase in ACh con-
centration in the myocardium mediates the cardioprotective effects 
of remote preconditioning. It is also unclear which of the abdominal 
n. vagus fibres—afferent or efferent—are involved in this phenom-
enon. The known humoral factors that have the closest relationship 
with neural mechanisms are GLP-1 and nitrite. However, the source 
of their release in response to remote ischaemic stimulus is not clear. 
GLP-1 glucagon-like peptide-1, ACh acetylcholine
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recruitment of intrinsic cardiac ganglia. Their subsequent 
study, demonstrating that coronary effluent from a precon-
ditioned isolated heart could protect another isolated heart, 
but not isolated cardiomyocytes, also contributed to the 
hypothesis of the importance of intrinsic cardiac ganglia in 
the mechanisms of direct ischaemic preconditioning [102].
Since the first demonstration of the possibility to trans-
fer ischaemic preconditioning cardioprotection with blood 
[32], the attention of several research groups has focused 
on identifying the humoral factor responsible for RIPre. 
Several candidate humoral factors of RIC have been pro-
posed, including stromal cell-derived factor-1 [30], nitrite/
nitric oxide [110], interleukin-1α [41], interleukin-10 [19], 
microRNA-144 [88], apolipoprotein A-I [57], alpha-ketoglu-
tarate-dependent dioxygenase Egln1 [101] and glucagon-like 
peptide-1 (GLP-1) [7, 8]. However, for the purpose of this 
review, we focus on two of the proposed humoral media-
tors that are most relevant to the ‘neural hypothesis’ of RIC, 
namely nitrite/nitric oxide [110] and GLP-1 [7, 8].
Using an in vivo mouse model, Rassaf et al. demon-
strated that shear stress-dependent stimulation of endothe-
lial nitric oxide (NO) synthase within a femoral artery by 
RIPre yields a substantial release of NO. This NO is subse-
quently oxidized to nitrite and transferred humorally to the 
myocardium, where it reduces infarct size caused following 
30-min myocardial ischaemia and 24-h reperfusion [110]. 
In addition, a series of experiments in which plasma from 
healthy volunteers subjected to RIPre was perfused through 
isolated mouse hearts, identified plasma nitrite as the car-
dioprotective agent [110]. Similarly, in a recent study by 
Hauerslev et al., scavengers of NO attenuated RIPre-induced 
protection in rat hearts [47]. Previously, it had been shown 
that either stimulation of cervical vagal nerves or perfusion 
with acetylcholine is associated with NO release in an iso-
lated rabbit heart via the neuronal isoform of NO synthase 
[16]. Interestingly, in an earlier study, bilateral vagal nerve 
stimulation in rabbits was followed by an increase in nitrite 
formation at the level of the stomach and the colon [62]. 
In terms of planning future clinical studies on the effect of 
RIC, it is important to keep in mind that exogenous NO [98] 
and nitroglycerin [35, 50, 148, 155] have been shown to be 
able to reduce infarct size, and may therefore, potentially 
interfere with RIC.
The results obtained by Mastitskaya et al. [92] suggest 
that visceral organs, innervated by the posterior gastric 
branch of the vagus nerve, are the likely source of a humoral 
factor (or factors) of RIC cardioprotection. This finding is 
interesting as it provides the first potential mechanism unit-
ing the ‘neural’ and ‘humoral’ hypotheses of RIC. Apart 
from nitric oxide [62], GLP-1 appears to be the most likely 
candidate for this role. Its release from the L-cells of the 
intestine is modulated by vagal efferent (motor) activity 
[58, 115] and there is also evidence that GLP-1 may interact 
with vagal sensory fibers innervating the viscera [58]. The 
molecular weight of GLP-1 is 3.3 kDa thereby satisfying the 
key criteria of the humoral preconditioning factor (including 
molecular weight of less than 8 kDa), suggested by Lang and 
colleagues on the basis of the proteomic analysis of blood 
samples obtained from experimental animals receiving the 
RIPre stimulus [85]. Studies conducted in animal models by 
the Yellon group [13, 14], and subsequently by others [111], 
demonstrated potent cardioprotection by GLP-1 receptor 
(GLP-1R) activation. The efficacy of GLP-1R agonists in 
limiting infarct size has also been shown in clinical trials on 
STEMI patients [90, 144]. Later, Basalay et al. showed that 
GLP-1 mediates cardioprotection by RIC, and demonstrated 
that cardioprotection induced by GLP-1R activation is medi-
ated by a mechanism involving M3 muscarinic receptors [7, 
8]. The location of these M3 muscarinic receptors, mediat-
ing the infarct-limiting effect of RIPre, is not yet established.
The main extracellular signaling molecules that 
have been shown to be involved in cardioprotection by 
RIPre  include opioids, bradykinin and adenosine [79]. 
Opioid peptides can be secreted from cardiac nerves 
or produced in the cardiomyocytes themselves [107]. 
Shimizu et al. demonstrated that the protective effect of 
dialysate from a donor limb subjected to RIC, on isolated 
cardiomyocytes is blocked by pre-treatment of the car-
diomyocytes with the opiate receptor blocker naloxone 
[122]. These results suggest that opioid receptors involved 
in RIC are located in cardiomyocytes and not connected 
with neural activation. On the other hand, in another 
study, hexamethonium abolished the protection provided 
by intramesenteric bradykinin infusion [119]. Regard-
ing bradykinin, it is worth mentioning that it is degraded 
rapidly by angiotensin-converting enzyme (ACE) [136], 
while ACE inhibitors and angiotensin-1 receptor antago-
nists [63] mimic its cardioprotective effects. The role of 
adenosine in RIC cardioprotection is still controversial, 
being confirmed in a mouse model [120], but not a porcine 
model [48].
Analysis of the concentrations of metabolites in plasma 
samples of patients subjected to RIC revealed an increase 
in glycine concentration following RIC [23]. This is rel-
evant to the current review, as glycine is known to be an 
inhibitory neurotransmitter in the central nervous sys-
tem, and specifically, in parasympathetic nuclei [22, 131, 
132]. In the above-mentioned study, the injection of gly-
cine mimicked the protective effects of RIC in rats [23]. 
García-Dorado’s group demonstrated that glycine exerts 
cross-species cardioprotection against infarction through 
glycine receptor activation [66]. The potential involvement 
of glycine signalling in RIC-induced cardioprotection 
should be borne in mind when planning clinical trials, as 
certain drugs, such as Ketamine [137], can inhibit glycine 
neurotransmission to cardiac vagal neurons.
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The importance of understanding the mechanism of 
RIC cardioprotection is clearly demonstrated by the neutral 
results of two recent multicentre trials—ERICCA and RIPH-
eart, in which the majority of the patients were given propo-
fol as part of the anesthesia protocol [31, 96]. Importantly, it 
had previously been shown that propofol inhibits neurotrans-
mission to cardiac vagal neurons in the nucleus ambiguous 
[138]. On the other hand, propofol had been shown to cause 
the enhanced nitrite production in cultured myocytes [146], 
whereas nitrite is known as one of the humoral mediators of 
RIPre [110]. The results of small-scale clinical trials com-
pleted in 2012 and 2014 confirmed the importance of the 
anesthetic regime, showing that RIPre during isoflurane but 
not during propofol anesthesia decreased myocardial damage 
in patients undergoing CABG surgery [82] or elective aortic 
valve replacement [9, 10]. A recent experimental study also 
clearly demonstrated that propofol, but not sevoflurane, abol-
ished the infarct-limiting effect of RIPre in rats in vivo [11]. 
In a more recent single-centre study with a neutral effect of 
RIC in CABG patients, propofol was purposefully avoided 
[99]. However, in this study, the anesthetic protocol included 
fentanyl, which has been shown to inhibit neurotransmission 
to cardiac vagal neurons in the nucleus ambiguous [45]. It 
could also be argued, however, that fentanyl or sufentanil 
did not abolish RIC-induced cardioprotection in other clini-
cal studies [9, 133]. Although there are multiple possible 
reasons for the lack of protection in these studies, as has 
been extensively discussed [25, 39, 55], the suppressed vagal 
system is likely to have contributed.
The effect of an anesthetic protocol on RIC efficacy was 
revealed in a Bayesian network meta-analysis of 55 rand-
omized trials, which included 6921 patients undergoing car-
diac surgery. The use of volatile agents and the combination 
of volatile agents with remote preconditioning were found 
to be associated with a reduction in mortality at the longest 
follow-up time available, when compared to total intrave-
nous anesthesia [151]. Furthermore, it was observed that 
the combination of RIC with volatile agents was associated 
with a reduction in mortality when compared to RIC with 
total intravenous anesthesia [151].
Unresolved questions and discrepancies 
on the mechanisms of cardioprotection 
by remote ischaemic conditioning
Although the degree of cardioprotection conferred by RIPre 
and delayed RIPost is similar, the underlying mechanisms 
seem to be distinct [5]. In the Basalay et al.’s study (2012), 
the infarct-limiting effect of delayed RIPost was not affected 
by either vagotomy or peripheral denervation, as opposed to 
the effect of RIPre [5]. As peripheral or especially parasym-
pathetic denervation, can potentially represent real clinical 
situations with patients suffering from peripheral polyneu-
ropathies of different etiologies, or exposed to drugs with 
vagolytic effects, these results allow us to predict a lack 
of cardioprotective benefit from RIPre in these cohorts of 
patients. On the other hand, delayed RIPost could potentially 
be more effective in the same patients, being less susceptible 
to innervation impairments, though no clinical trials demon-
strating this have been completed so far.
The other missing part in our knowledge is the mecha-
nism of vagally mediated RIPre cardioprotection. The feasi-
bility of vagally mediated cardioprotection (i.e., RIPre) in a 
left ventricle, which is known to be only sparsely innervated, 
can be explained by the observation that there is a local ace-
tylcholine (ACh) synthesis system in the myocardium [37, 
69, 109]. This system is positively modulated by cholinergic 
stimuli [69]. Conversely, atropine reduces the basal ACh 
content [69]. It has been shown that either bilateral vagot-
omy [5] or direct inhibition of the parasympathetic motor 
neurons in the central nervous system [93], or atropine treat-
ment [34] abolishes the infarct-limiting effect of RIPre. Yet, 
it is not clear whether it is the increase of acetylcholine con-
centration that mediates the cardioprotective effect of RIC. 
There are a number of experimental observations relevant to 
the assumption that it is indeed acetylcholine which medi-
ates RIPre. First, in support of this hypothesis, the hearts 
from transgenic mice overexpressing choline acetyltrans-
ferase (ChAT)—the main ACh-synthesizing enzyme in car-
diomyocytes—are more resistant to ischaemia–reperfusion 
injury than wild-type hearts [70]. And second, RIC increases 
both ChAT expression and ACh content in mice hearts [68, 
100]. However, there are also experimental data that con-
tradict this hypothesis. In this regard, it has been shown that 
acute myocardial ischaemia provoked an increase of ACh 
concentration in an ischaemic myocardium, and vagotomy 
did not affect this increase [76], while on the other hand, 
vagotomy abolished the infarct-limiting effect of RIPre [5]. 
This indicates that the loss of RIPre-mediated cardioprotec-
tion in vagotomised rats [5] might be caused by some other 
factors rather than a decrease in ACh concentration. Another 
indirect argument suggesting that ACh concentration may 
not be of critical importance for ischaemic precondition-
ing is that vagotomy abolishes the myocardial interstitial 
ACh release induced by brief myocardial ischaemia [75]. 
On the other hand, bilateral vagotomy does not attenuate the 
infarct-limiting effect of direct ischaemic preconditioning 
[5], which indicates that ACh concentration in the myocar-
dium does not correlate with the degree of cardioprotection. 
Currently, there are no data revealing whether RIPre causes 
further increase of ACh concentration in the ischaemic myo-
cardium in comparison to the myocardial ischaemia itself, 
and whether vagotomy prevents this additional increase. The 
answer to this question is even more difficult, as the degree 
of ACh increase during myocardial ischaemia varies from 
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study to study, depending on the animal species, samples and 
techniques used, as well as on the duration of the ischaemic 
episode [74, 76, 102].
Despite the lack of experimental data that would unequiv-
ocally answer the question of myocardial ACh concentration 
in RIC-mediated cardioprotection, there are several observa-
tions that may shed some light on this aspect. In this respect, 
it was demonstrated that cardiomyocytes of adult, but not 
neonatal rats, are able to synthesize, transport and excrete 
ACh in the heart [109]. The expression level of ChAT and 
the amount of ACh excreted were also significantly down-
regulated in cardiomyocytes of old animals [109]. If ACh 
concentration in myocardium determines the potency of pro-
tection by RIC, we may expect that RIC would be less effec-
tive in children and aged people. Indeed, RIPre was actually 
shown to impair ventricular function and increase infarct size 
in an isolated neonatal rabbit heart [118]. An earlier, small-
scale clinical study had demonstrated myocardial-protective 
effects of RIPre in children [26]. However, in a more recent 
clinical trial performed on 299 children (aged neonate to 
17 years), RIPre was not associated with important improve-
ments in clinical outcomes and physiological markers after 
cardiac surgery [95]. It should be noted, however, that there 
was no standardized protocol of anesthesia in this study, 
and more than half the patients were exposed to propofol 
[95]. The effect of RIC in elderly patients (> 70 years) was 
investigated in the CONDI trial, and found to be equally 
as protective as in younger patients [126]. Similarly, in the 
LIPSIA CONDITIONING trial, the combination of RIC and 
local ischaemic postconditioning was effective in both age 
groups—under and over 65 years old [36]. Similar results 
were obtained after the analysis of confounders of RIPre 
cardioprotection in patients undergoing coronary artery 
bypass grafting [80]. In a recent experimental study by 
Heinen et al., plasma of young male volunteers, subjected 
to RIC, reduced infarct size in isolated hearts from aged rats 
[49]. However, RIC plasma of aged male volunteers had no 
protective effect in young rat hearts [49]. This indicates that 
aging affects the RIC-induced release of a humoral factor, 
but not the susceptibility of myocardium to the protective 
effect of this phenomenon.
One of the main purposes for investigating the mecha-
nisms of endogenous cardioprotective phenomena is the 
potential to develop pharmacological therapy or electronic 
devices that can fully mimic its positive effects. These could 
have the advantage of being able to be applied or admin-
istered significantly more quickly than the RIC procedure, 
which requires up to 40 min. As RIPre/RIPer cardioprotec-
tion is mediated by the activation of vagal efferents [5, 93], 
it is logical to assume that vagal nerve stimulation could 
potentially reproduce the effects of RIC. The obvious 
question arising here is whether monolateral vagal nerve 
stimulation can achieve this goal. In experimental studies, 
electrical stimulation of right [3, 18, 20, 72, 73], left [123, 
124] or both vagal nerves [134] limited myocardial infarct 
size when started either before [18, 20, 72] or during [3, 
73, 123, 124, 134] myocardial ischaemia, or at the onset of 
reperfusion [18]. In a clinical study by Yu et al., low-level 
transcutaneous stimulation of the vagal branch within the 
area of the right tragus, in patients presenting with STEMI, 
was followed by the reduction of the incidence of reper-
fusion-related ventricular arrhythmia, the area under curve 
for creatine kinase-MB and myoglobin over 72 h, and blood 
levels of inflammatory markers [52, 150]. In the study by 
Basalay et al., the activity of only one vagal nerve—either 
right or left—was sufficient and contributed equally to medi-
ate cardioprotection established by RIPre. On the other hand, 
functional integrity of both nerves was required to establish 
cardioprotection when the remote conditioning stimulus was 
applied during myocardial ischaemia [6]. However, the dif-
ferences in the mechanisms of RIPre and RIPer leading to 
this difference [6] have not been explained. Another aris-
ing question is—whether electrical vagal nerve stimulation 
can completely mimic all aspect of RIC, which include the 
indirect stimulation of the release of humoral factors [52].
While the importance of the activation of parasympa-
thetic efferents in RIC-mediated cardioprotection is now 
unambiguous, the role of the sympathetic nervous system 
in this phenomenon has not been described clearly. How-
ever, it has been demonstrated that beta-blockers reduce 
infarct size in STEMI patients undergoing PCI [61], and 
this group of drugs is currently included in the guidelines 
for the management of these patients [60]. It has been shown 
that beta-adrenoreceptors are involved in the mechanisms of 
myocardial infarct-limiting effect of remote pre- and post-
conditioning of trauma [128, 129]. The existence of some 
common, inherent mechanisms, such as the activation of 
C sensory fibers and the K(ATP) channels for both remote 
preconditioning of trauma [65] and RIPre/RIPer [5, 83, 117], 
may be an argument to suggest that sympathetic beta-adren-
ergic activation is involved in the mechanisms of RIC car-
dioprotection. On the other hand, it has been demonstrated 
in rats that exercise training, which shares some molecular 
mechanisms with RIC [108, 121], augments the dynamic 
heart rate response to vagal but not sympathetic stimula-
tion [97]. Moreover, it is known that sympathetic nervous 
response to ischaemia–reperfusion injury is altered with 
RIPre [84]. In the CONDI trial, the infarct-limiting effect 
of RIC was preserved in beta-blocker users [126]. Although 
there are no available data on the effect of beta-blockers 
on the efficacy of RIC in other clinical trials with STEMI 
patients, the fact that remote conditioning was able to reduce 
infarct size in the clinical study, where almost all the patients 
were taking beta-blockers [36], reinforced the CONDI 
results (Table 1). Similarly, medication with beta-blockers 
was not a significant confounder of RIPre cardioprotection 
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in patients undergoing cardiac surgery [80]. In contrast, a 
meta-analysis of 15 clinical trials, including 1155 patients 
randomised to treatment with or without RIPre, showed 
an attenuated effect of this intervention in cardiosurgery 
patients on perioperative beta-blocker treatment [153].
Remote ischaemic conditioning of the brain
In addition to protecting the heart, RIC is potentially able 
to protect any other organ or tissue. It has been shown in a 
series of experimental studies that RIPre, RIPer, RIPost and 
delayed RIPost reduce brain infarct size in a rodent model of 
acute focal ischaemia/reperfusion brain injury [24]. Interest-
ingly, the reperfusion ‘time-window’, during which delayed 
RIPost was effective, seems to be longer in an ischaemic 
stroke model [104, 114] than in a STEMI model [4, 5]. In 
this regard, in a rat model with 100-min focal brain ischae-
mia, RIPost was able to reduce infarct size when initiated 
within 30 min of reperfusion [104]. Impressively, when sub-
ject to 30-min brain ischaemia, RIPost was effective up to 
3 h of reperfusion [114]. A meta-analysis of 13 randomized 
controlled trials, which included a total of 794 study partici-
pants who either suffered from, or were at risk from brain 
ischaemia and reperfusion injury, suggested that RIPost can 
offer cerebral protection for stroke patients [152]. Compared 
with controls, RIPost was shown to be able to reduce the 
recurrence of stroke or transient ischaemic attacks, levels of 
National Institutes of Health Stroke Scale score, modified 
Rankin Scale score and high-sensitivity C-reactive protein 
[152].
The studies on the mechanisms of RIC-induced neuro-
protection are quite scarce in comparison with the amount 
of studies on the mechanisms of RIC-induced cardiopro-
tection. Similar to RIC-induced cardioprotection, there is 
evidence for the involvement of the neural pathway in the 
mechanism of RIC of the brain [91, 104, 114, 139, 149], 
including the possible involvement of endogenous opioids 
[113, 154] and CGRP [113]. On the other hand, in one 
study, local electrical stimulation enhanced the neuropro-
tective effect of RIPost in a rat stroke model [145], which 
might suggest that the mechanisms underlying the thera-
peutic effects of these interventions are different. Pigna-
taro et al. demonstrated that the neuronal isoform of nitric 
oxide synthase takes part in the neuroprotective effect of 
RIPost [104]. Further investigation of the neuroprotec-
tive mechanism of RIC is important to establish the most 
effective and safe implementation of this phenomenon to 
clinical practice.
The activity of the cardiovascular system is continu-
ally modulated by the central nervous system, ensuring 
coordination and regulation of regional cardiac electri-
cal, mechanical and metabolic indexes throughout each 
cardiac cycle [2]. This fine regulation is provided by the 
neuronal elements, which are distributed from the level of 
the insular cortex to the intrinsic cardiac nervous system, 
and are in constant communication with one another [2]. 
In this regard, both ischaemic and haemorrhagic strokes 
can cause abnormalities in autonomic nervous system 
activity, followed by functional imbalance within the car-
diovascular system, and in certain situations—even by 
irreversible cardiomyocyte damage, determined as serum 
troponin elevation [33]. On the other hand, nociceptive 
sensory inputs arising from the ischaemic heart represent a 
stimulus that can evoke discord within and among different 
levels of the hierarchy of the neuronal elements connecting 
heart, brain and central nervous system [2, 54]. Bearing in 
mind the existence of these bidirectional feedback interac-
tions between the heart and brain [2], and specifically the 
involvement of brain subcortical structures in ‘remote pre-
conditioning reflex’ [44, 93], more detailed understanding 
of the mechanisms of RIC-induced neuroprotection would 
shed more light on the mechanisms RIC-induced cardio-
protection and myocardial ischaemia/reperfusion injury.
Table 1  The use of beta1-
blockers in clinical studies 
on the effect of remote 
ischaemic conditioning in 
patients undergoing primary 
percutaneous coronary 
interventions
RIC remote ischaemic conditioning, MSI myocardial salvage index, SPECT single-photon emission-com-
puted tomography, TnI troponin I, AUC area under curve, CK-MB creatine kinase-muscle/brain, MRI mag-
netic resonance imaging





Bøtker HE 2010 Denmark 333 15/15 Yes MSI (SPECT)
Rentoukas I 2010 Greece 96 99/100 n.s. Peak TnI
Crimi G 2013 Italy 100 13/20 Yes AUC CK-MB
Eitel I 2015 Germany 696 96/98 Yes MSI (MRI)
Verouhis D 2016 Sweden 93 10/15 No MSI (MRI)
Gaspar A 2018 Portugal 258 14/16 Yes Progression 
of heart 
failure
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Conclusions
Investigating the mechanisms of RIC is the essential step on 
the road to its translation to patient benefit, and specifically to 
the discovery of therapies or electronic devices, which would 
be able to mimic the beneficial effects of this phenomenon. 
Experimental and clinical data indicate that neural mecha-
nisms, known as the ‘remote preconditioning reflex’, have an 
important contribution into RIC phenomena. However, there 
are still gaps in our understanding of the neural mechanism:
• Though the mechanism of RIPre has been extensively 
investigated, the mechanism of delayed RIPost is less 
clear. According to experimental data so far, delayed 
RIPost could be effective in patients with neural impair-
ments, in whom the anti-ischaemic effect of RIPre is not 
expected.
• Although the involvement of vagal nerves in RIPre and 
RIPer is certain, an important question in terms of future 
drug discovery is whether these phenomena provide car-
dioprotection via the increase of ACh concentration in 
left ventricle myocardium.
• In terms of the future possibility to mimic or increase 
the effects of RIC using direct vagal nerve stimulation, a 
gap in the current knowledge is: why the effect of mon-
olateral vagotomy is different for infarct-limiting effect 
of RIPre and RIPer.
• Sympathetic involvement in RIC is another gap in our 
understanding of these phenomena. The interaction of 
the sympathetic and parasympathetic nervous systems is 
fundamental and complex, so that, from a translational 
point of view, it would hardly be possible to modulate 
one of them without influencing the other. Notably, drugs 
modulating sympathetic activity are widely used in rou-
tine clinical practice—this fact is important to bear in 
mind when designing clinical studies.
• Revealing the mechanisms of RIC-induced neuroprotec-
tion is an important goal for future research not only to be 
able to use this phenomenon most efficiently in clinical 
practice, but also as it could help better understand the 
mechanisms of cardioprotective effects of these phenom-
ena.
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